NCT06882538 The Effect of Mindfulness-Based Psychoeducation Programme Given Individually to Schizophrenia Patients on Internalised Stigma and Healthy Lifestyle Behaviours
| NCT ID | NCT06882538 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Kastamonu University |
| Condition | Schizophrenia Disorders |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-02-14 |
| Primary Completion | 2025-02-20 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 40 participants in total. It began in 2025-02-14 with a primary completion date of 2025-02-20.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Schizophrenia is a chronic, recurrent and disabling illness that usually lasts a lifetime and causes serious problems in quality of life and functioning. Psychoeducation programmes added to drug treatment in the treatment of schizophrenia have been shown to increase the knowledge of patients and their relatives about the disease, coping skills, prevention of exacerbations and relapses of the disease, social functioning, insight into the disease, compliance with drug treatment and quality of life. Rehabilitated individuals diagnosed with schizophrenia who are registered and continuing at Kastamonu Training and Research Community Mental Health Centre will constitute the population, and individuals who continue between April 2024 and May 2024 will constitute the sample. The research will be conducted with schizophrenic patients in a pre-test-post-test, experimental and control group experimental design. Power analysis will be performed to determine the number of people to be sampled and calculated with the G\*Power 3.1 programme. 40 people will be reached in the groups, 20 people in the experimental group and 20 people in the control group. In the evaluation of the data, descriptive statistical methods (Mean, Standard deviation) as well as the correlation test will be used to evaluate the relationship between the average scores before and after the training in the comparison of quantitative data. Wilcoxon related sample test will be used to make comparisons before and after the training. Personal Information Form, Internalised Stigma Scale in Mental Illness (ISIS) and Healthy Lifestyle Behaviours (HBSB) scale will be used to collect the data. Awareness-based psychoeducation programme will be applied to the experimental group. The aim of psychoeducation is to create a change in knowledge and behaviour towards healthy lifestyle behaviours (1- Self-actualisation, 2- Health responsibility, 3- Exercise, 4- Nutrition, 5- Interpersonal support, 6- Stress management) by reducing internalised stigma. Therefore, it will be evaluated whether the applied psychoeducation programme creates the intended change in knowledge and behaviour. This study will be conducted to examine the effect of a 6-week 12-session self-awareness-based psychoeducation programme given to schizophrenia patients on internalised stigma and healthy lifestyle behaviours. In this study, schizophrenic patients will be provided with regular psychoeducation to provide individual support, to ensure the development of coping skills for self-protection, and to gain knowledge and skills to gain a healthy lifestyle. After the prepared psychoeducation, a training guide will be created for the participants and will be given after the training, thus ensuring continuity of education.
Eligibility Criteria
Inclusion Criteria: 1. Having been diagnosed with schizophrenia 2. TRSM registered and continuing 3. Acceptance to work and training Exclusion Criteria: 1. Have not been diagnosed with schizophrenia 2. If he/she does not agree to participate in the study 3. If not registered with TRSM
Contact & Investigator
Havva K KAÇAN, ASSOCIATE PROFESSOR DOCTOR
PRINCIPAL INVESTIGATOR
Kastamonu University
Frequently Asked Questions
Who can join the NCT06882538 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Schizophrenia Disorders. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06882538 currently recruiting?
Yes, NCT06882538 is actively recruiting participants. Contact the research team at hkacan@kastamonu.edu.tr for enrollment information.
Where is the NCT06882538 trial being conducted?
This trial is being conducted at Kastamonu, Turkey (Türkiye).
Who is sponsoring the NCT06882538 clinical trial?
NCT06882538 is sponsored by Kastamonu University. The principal investigator is Havva K KAÇAN, ASSOCIATE PROFESSOR DOCTOR at Kastamonu University. The trial plans to enroll 40 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.